LIPO - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Lipella Pharmaceuticals

Lipella Pharmaceuticals focuses on repurposing profitable urology drugs while facing binary risks associated with early-stage testing. The year-over-year sales growth percentage (over 4 quarters) illustrates the current trend, where 714.70 serves as the current parameter value. Business stability relies on a liposomal delivery platform for bladder agents and stringent patents within the cystitis treatment niche.
פילוחי נתונים אנליטיים מרוכזים עבור Lipella Pharmaceuticals, Inc. (LIPO)

Lipella Pharmaceuticals (LIPO) is a biotech startup whose market capitalization is based on the prospects of bladder pathology therapies rather than current turnover. Analyzing the year-over-year sales trend over the last 12 months, an investor sees TTM revenue dynamics that measure operational growth rates relative to the previous year, which in this case confirms the absence of commercial sales prior to the completion of clinical trials.